Healthy Ageing. From Basic Science to Clinical Applications and New Business. Jan Sikkema Center for Development and Innovation June 16, 2016
|
|
|
- Antony Black
- 6 years ago
- Views:
Transcription
1 Healthy Ageing From Basic Science to Clinical Applications and New Business Jan Sikkema Center for Development and Innovation June 16, 2016
2 Groningen Broad Research University 11 faculties > students 625 professors > 450 PhD theses/year 120 Master degree programs Number 5 in top 10 best places to work in academia in 2012 according to The Scientist
3 Groningen University Medical Center patient visits beds students 214 PhD theses 2015 Medicine, Dentistry, Movement sciences
4 CORE RESEARCH THEMES INSPIRED BY SOCIETAL CHALLENGES ENERGY HEALTHY AGEING SUSTAINABLE SOCIETY
5 Adding healthy years to life Health Quality of Life Prevention Ambition Treatment birth Life course Age
6 Healthy Ageing theme embedded in Research of the University Programs
7 ERIBA European Institute for the Biology of Ageing European Research Institute on the Biology of Ageing 10 world s leading scientists in the field of ageing and its associated diseases NWO Systems Biology Center for Energy Metabolism and Ageing Skoltech Center for Stem Cell Research
8 LifeLines cohort participants 3 generations 30 years LifeLines data: Questionnaires Measurements Biological samples Registries + GP data
9 Brain research entire spectrum from preclinical to clinical research Alzheimer s Center Basic Brain Ageing Research Neuroimaging Mental Health/ Epidemiology University Center for Geriatric Medicine Brain Ageing Unit Patient cohorts Clinic Neuroinflammation Neuro-imaging Biomarkers
10 Maturation and ageing of the Microbiota: the new frontier Changes in microbiota composition associated with altered metabolism Role of microbiota and food fibers in maturation of the immune system
11 Antimicrobial Resistance CESAM: CENTER for ANTIMICROBIALS RESEARCH Brings together medical microbiology, biochemistry, organic chemistry and drug delivery expertise to fight antimicrobial resistance by developing new antibiotics, new strategies for delivery and better protocols. From WHO Global Report on surveillance 2014;
12 EIT Health: Innovation for Active Ageing and Healthy Living Large industry + excellent academic partners; 2.1 billion euro budget ( funding); UK NOD E SCANDINAVIAN NODE Södert örn Council s Involvement regional (SME) network. FRENCH NODE GERMAN NODE SPANISH NODE BENELUX NODE
13 University Medical Center Groningen LifeLines Pre-clinical and pharamaceutical Research New buildings: a.o. ERIBA Healthy Ageing Bio-GMP Campus facility Netherlands Clinical Research, incl. advanced imaging facilities Patients Spin-off companies Patients Patients Spin-off companies Main entrance Valorisation Center Spin-off companies NH Hotel
14 Bridge basic science and application Acknowledged expertise areas High end fundamental and pre-clinical research Advanced clinical research and clinical practice Engage high-tech spin-offs and start-ups Form multi-disciplinary consortia: Biomarkers, ehealth, Early Life Nutrition
15 Dairy Campus Health Hub
16 Health Hub: a new approach Expertise Center for MedTech Research linked to application SME s, start-ups and industry Education and training program for students from University and Vocational schools Ideation and design Product development Professional education
17 Strategic alliances with industry
18 Strategic alliances with industry
19 Strategic alliances with industry
20 Business-centered innovation clusters Pharma ICT/e-Health Diagnostics B-Bay Medical Technology BMC Nutrition ELN
21 High-tech start-ups 300 start-ups and student companies p.a high-tech 100 LifeSciences companies 1.5 bn euro turnover 2700 employees
22 DIAGNOSIS Non-invasive assessment of advanced glycation endproducts as a marker for metabolic health
23 DRUG DELIVERY InnoCore Pharmaceuticals is specialized in the development of long acting and minimally invasive injectable drug delivery products for the treatment of chronic diseases
24 TRANSPLANTATION Preservation equipment Preservation of donor organs for better treatment and survival of patients undergoing kidney, liver and lung transplantation
25 MEDICAL TECHNOLOGY Advanced Ergonometry for better assessment of physical performance of (rehab) patients and athletes
26 SERIOUS GAMING for medical skills training The Laparoscopic Skills Training Wii Game
27 Groningen: exceptionally entrepreneurial
28
From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014
From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the
The Role of Public-Private Partnerships & Evidence Generation
The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created
Innovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
What IMI means for POLAND
What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)
The Innovative Medicines Initiative Socio-economic impacts
The Innovative Medicines Initiative Socio-economic impacts Pierre Meulien, IMI Executive Director European Innovation Summit European Parliament 08.12.2015 Closed & open innovation Filing Approval HTA
Joint Technology Initiative: Innovative Medicine Initiative
Joint Technology Initiative: Innovative Medicine Initiative Dr John E Butler-Ransohoff Global External Innovation and Alliances Bayer HealthCare AG, Berlin/Wuppertal Bari, 30 April 2015 Largest Public
The Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels
The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of
Promoting collaboration: Strategies and programs within health research and innovation
Promoting collaboration: Strategies and programs within health research and innovation Anne K Fahlvik, PhD, Executive director Mari K Nes, PhD, Special Adviser The Research Council of Norway The Research
NORDIC LIFE SCIEN SWEDEN S LIFE SCIENCE STRATEGY ANTIBIOTIC RESISTANCE THE LEADING LIFE SCIENCE BUSINESS MAGAZINE 169 SEK / 20 EUR / 25 USD
NORDIC LIFE SCIEN THE LEADING LIFE SCIENCE BUSINESS MAGAZINE 169 SEK / 20 EUR / 25 USD // UMEÅ // KUOPIO // TROMSØ ANTIBIOTIC RESISTANCE SWEDEN S LIFE SCIENCE STRATEGY ILLUSTRATION AJAK ARCHITECTS ALL
EU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
Company Profile. Welcome at VitaK Innovation in Life Science. We create unique innovation tools for better healthcare
Company Profile Welcome at VitaK Innovation in Life Science We create unique innovation tools for better healthcare Introduction Mission Statement History Management Team Divisions Patents Contact Mission
Biopeople at a Glance
Biopeople at a Glance Future Directions in Regulatory Science Copenhagen 21 April 2016 Per Spindler, Director www.biopeople.dk Welcome to Biopeople Biopeople, Faculty of Health and Medical Sciences, University
The Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain
The Innovative Medicines Initiative Pierre Meulien 12.01.2017 CNIO, Madrid - Spain IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2020 Pharma industry 2.5 bn EU contribution from FP7
Overview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017
FNR Overview of the Luxembourg biomedical and health research ecosystem FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017 Research in Luxembourg Luxembourg : a young research location Creating structures
Belgium, a European leader in clinical trials
Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials
- OMICS IN PERSONALISED MEDICINE
SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary
Konica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
Protein research and bioinformatics
Protein research and bioinformatics LauritzenConsulting Content and application Proteins are the fundamental building blocks of life. Research in Greater Copenhagen focuses on the significance of proteins
MONASH BIOMEDICINE DISCOVERY INSTITUTE. At a Glance. monash.edu/discovery-institute
MONASH BIOMEDICINE INSTITUTE At a Glance monash.edu/discovery-institute MONASH BIOMEDICINE INSTITUTE WHO WE ARE An institute with the scale and scope to tackle major research questions. We are one of the
Per Morten Sandset Japan-UiO cooperation within health and care research status and opportunities
Per Morten Sandset p.m.sandset@medisin.uio.no Japan-UiO cooperation within health and care research status and opportunities Japan-UiO cooperation within health and care Brief presentation of the University
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
Introduction to IMI. Pierre Meulien Executive Director Innovative Medicines Initiative
Introduction to IMI Pierre Meulien Executive Director Innovative Medicines Initiative What is the Innovative Medicines Initiative? EU funding goes to: - universities - SMEs - patient groups etc 2.5 bn
6. Amsterdam Institute for Molecules, Medicine and Systems (AIMMS) VU University Amsterdam
6. Amsterdam Institute for Molecules, Medicine and Systems (AIMMS) VU University Amsterdam Assessments: Quality Relevance Viability AIMMS 1 2 1 6.1 Introduction and research area The Amsterdam Institute
Building the Europe of Knowledge
Building the Europe of Knowledge 7 th Framework Programme 2007-2013 Nanotechnology! All information preliminary! FP7 1. Capacities: Infrastructures 2. People: Erasmus, Marie-Curie 3. Ideas: ERC 4. Cooperation:
The overview of Estonian biotechnology sector (2012)
The overview of Estonian biotechnology sector (2012) Olavi Otepalu 15.06.2012, Tallinn Bioeconomy in the Baltics. Inspiration conference. Defining the biotechnology sector Always necessary prior to specify
Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
Almac Overview.
Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide
Panakes overview. Closed Jan 16 an alternative investment fund managed by a SGR authorized by Bank of Italy
10 July 2018 Investments by the Panakes Fund are supported by the INNOVFIN SME Venture Capital (Horizon 2020) and through financial backing of the European Union under the Equity Facility for Growth (COSME)
KPI Definition Comment Relates to Baseline Target
IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year
Innovative Medicines Initiative Personalised Medicine Cancer and Diabetic Research. Krakow Biotechnology congress - 13 October 2011
Innovative Medicines Initiative Personalised Medicine Cancer and Diabetic Research Krakow Biotechnology congress - 13 October 2011 Fatiha Sadallah IMI Scientific Manager What is the Innovative Medicines
2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships
2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships Call Identifier: TMA2017IF The purpose of this Call for Proposals is to provide funding towards actions that aim to support
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative
OCTIMET. Company Profile
OCTIMET Oncology NV (OCTIMET) is a privately held Belgian based life science company specialized in accelerating the development of oncology therapies by providing rapid clinical proof of concept through
Delivering the NIHR Central Commissioning Facility
Delivering the NIHR Central Commissioning Facility About the NIHR The National Institute for Health Research is funded through the Department of Health to improve the health and wealth of the nation through
The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic
The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic 1 The Irish Biomarker Network -Inaugural Workshop Improved Translation of Biomarkers to the Clinic Overview
The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England
The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.
The Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
European Technology Platform Central concept
http://etp.ciaa.eu European Technology Platform Central concept A new instrument to strengthen the European-wide innovation challenge (and address the so-called European Paradox), An (industry-led) framework
L A B O R M A R K E T B R I E F I N G S S E R I E S
L A B O R M A R K E T B R I E F I N G S S E R I E S LABOR MARKET INFORMATION FOR RESEARCHERS THE LIFE SCIENCE AND PHARMACEUTICALS SECTOR IN EUROPE L I F E S C I E N C E A N D P H A R M A C E U T I C A
Webinar IMI2 Call 14 Opportunities for SMEs
Webinar IMI2 Call 14 Opportunities for SMEs 19 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Opportunities for SMEs Colm Carroll, IMI Questions & answers How to use GoToWebinar - audio
Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development
Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development Toshio MIYATA Tohoku University Graduate School of Medicine United Centers for Advanced Research and Translational Medicine
Supplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/6/242/242cm6/dc1 Supplementary Materials for Sandbox: Building and Sharing Resources This PDF file includes: Mark David Lim E-mail: mlim@fastercures.org
The room was more than 3/4 full with greater than 150 people in attendance.
Summary The room was more than 3/4 full with greater than 150 people in attendance. The questions were well distributed across all four panelists. All the Panelists were very interactive and were able
Data Aggregation Across Diseases and Between Stakeholders. Enrique Avilés, Chief Technology Officer
Data Aggregation Across Diseases and Between Stakeholders Enrique Avilés, Chief Technology Officer 1 Goals, structure, governance and expertise enable effective collaboration C-Path consortia 4Q 2015 Twelve
Stem Cell Research: Identifying emerging high priority policy issues
The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November
Research and development case study. Human health research
Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published
The Swedish Foundation for Strategic Research (SSF) announces a. call for proposals in the areas of
1(8) 2008-09-16 Announcement The Swedish Foundation for Strategic Research (SSF) announces a call for proposals in the areas of Design, development and validation of new predictive models and new biomarkers
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration
INFECTIOUS DISEASES WE ARE LEADING THE WAY.
INFECTIOUS DISEASES WE ARE LEADING THE WAY. NO1 WORLD S LARGEST COLLECTION OF TICK CELL LINES OF MEDICAL AND VETERINARY IMPORTANCE ONE OF THE BIGGEST COLLECTIONS OF TROPICAL VENOMOUS SNAKES IN THE COUNTRY
INFECTIOUS DISEASES WE ARE LEADING THE WAY.
INFECTIOUS DISEASES WE ARE LEADING THE WAY. NO1 WORLD S LARGEST COLLECTION OF TICK CELL LINES OF MEDICAL AND VETERINARY IMPORTANCE ONE OF THE BIGGEST COLLECTIONS OF TROPICAL VENOMOUS SNAKES IN THE COUNTRY
MARCH 15-16, 2018 PARIS PALAIS BRONGNIART. An event of PROGRAM
MARCH 15-16, 2018 PARIS PALAIS BRONGNIART An event of PROGRAM DIAGNOSIS - March 15, 12:15-13:15 Precision diagnostic: genomics plans panorama French genomic national plan: PFM2025 England Genome: 100 000
Innovative Medicines Initiative (IMI) and other Public Private Partnerships: Educational Ambitions
Innovative Medicines Initiative (IMI) and other Public Private Partnerships: Educational Ambitions Oslo EAFP 19 June 2009 1200 km 2 2 Billion EURO 1 Billion Euro 1 Billion Euro Public Private Partnership
REIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
Rare diseases in the 7th EU Framework Programme for Research and Technological Development
Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of
The NIHR. NIHR: health research in Professor Stephen Smye Specialty Cluster Lead, NIHR CRN, King s College London. Clinical Research Network
The NIHR NIHR: health research in 2030 Professor Stephen Smye Specialty Cluster Lead, NIHR CRN, King s College London Why? https://www.bhf.org.uk/publications/statistics/ trends-in-coronary-heart-disease-1961-2011
SSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview
SSPPS STRATEGIC PLAN Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice April 30, 2012 Overview Here we present the 2012-2017 strategic plan for the Skaggs School of Pharmacy
Science, Demographic Change and Wellbeing in Horizon 2020
Science, Demographic Change and Wellbeing in Horizon 2020 "L Europa e la Salute: le politiche sanitarie e le diseguaglianze sociali in sanità", Regione Basilicata Matera, 28 maggio 2014 Rosanna D'Amario
Presidential Commission for the Study of Bioethical Issues 2 nd meeting September
Presidential Commission for the Study of Bioethical Issues 2 nd meeting September 13 14 2010 David B. Weiner, Ph.D. Professor Department of Pathology and Laboratory Medicine University of Pennsylvania
Webinar IMI2 Call 13 CONCEPTION continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
Webinar IMI2 Call 13 CONCEPTION continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now 11 December 2017 15:00 CET Agenda How to use GoToWebinar
Centre for NanoHealth
Steve Conlan PhD An integrated collaborative base for businesses in Wales Director - Reproductive Biology & Cancer Research Institute of Life Science School of Medicine Unique interdisciplinary R&D environment,
Innovative Medicines Initiative - the story so far
Innovative Medicines Initiative - the story so far Ruxandra Draghia-Akli MD PhD Director Health, Research & DG Health Research at a Crossroads Are Public-Private Partnerships the Way Forward? European
Research Strategy Delivering internationally excellent research for a healthy, safe and sustainable society
Research Strategy 2016-2018 Delivering internationally excellent research for a healthy, safe and sustainable society Mission The College of Biomedical and Life Sciences aims to deliver internationally
So many science careers: find your own niche
So many science careers: find your own niche Kristin Breitschopf sanofi-aventis Deutschland GmbH PhD degree and what next? Scientists have a wide range of career options Huge diversity of career opportunities
Workshop 4: Data Revolution (Room Louis Armand)
Workshop 4: Data Revolution (Room Louis Armand) Moderator: Remi Salomon PhD, Vice-Chairman, AP-HP (FR) @APHP Roland Eils Data Management and Genomics Computing, Cancer Research Institute DKFZ (G) @CaptainSysBio
Nanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
Defining the Expertise for the 21 st Century Neuroscience Workforce. James E. Barrett, Ph.D. Professor and Chair
Defining the Expertise for the 21 st Century Neuroscience Workforce James E. Barrett, Ph.D. Professor and Chair Department of Pharmacology and Physiology Drug Discovery and Development Program at Drexel
EnTranCe: Centre of Expertise Energy
EnTranCe: Centre of Expertise Energy If we want things to stay as they are, things will have to change. Dr. Ir. Jan-jaap Aue Hanze University of Applied Sciences Hanze University of Applied Sciences, Groningen
E&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015
E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015 Education adapted to demand? Declining number of students choosing science Education still
ENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY
BIOANALYTICAL SOLUTIONS FOR BIOTHERAPEUTICS AND SMALL MOLECULE THERAPEUTICS ENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY MARCH 15, 2017 AIT BIOSCIENCE, LLC BIOANALYSIS TO SUPPORT
HESI VALUE: Translational Safety Biomarker Assessment of Neurotoxicity Proposal
HESI VALUE: Translational Safety Biomarker Assessment of Neurotoxicity Proposal Jesse L. Goodman, MD, MPH US Food and Drug Administration Emerging Issues Session HESI Annual Meeting 12 June 2012 Prague,
Tampere is the Fastest Growing Life Science Center in Finland
Tampere is the Fastest Growing Life Science Center in Finland Tampere has a combination of multi-disciplinary, technological, bio-medical and medical expertise in education, research, healthcare and business
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER
All research lines at the LMU have a strong methodological focus
Content: Genetic Epidemiology and Statistical Genetics in Complex Diseases... 2 Molecular Epidemiology of Complex Phenotypes... 2 Clinical Trials and Translational Medicine... 3 Clinical Epidemiology and
EIB Support in Life Sciences. Shiva Dustdar Head of Division, Innovation Finance Advisory European Investment Bank BIO-Europe Berlin, 7 November 2017
EIB Support in Life Sciences Shiva Dustdar Head of Division, Innovation Finance Advisory European Investment Bank BIO-Europe Berlin, 7 November 2017 EIB at a glance The EU bank: Established in 1958 Shareholders
Inaugural Fraunhofer Delaware Technology Summit
Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu
Newsletter. NeuroVive has ambitious goals for January New pharmaceuticals can revolutionize the care of severely ill patients.
Newsletter January 2019 NeuroVive has ambitious goals for 2019. New pharmaceuticals can revolutionize the care of severely ill patients. Read the exciting interviews with some of the people behind the
Flanders, a health(y) ecosystem.
Flanders, a health(y) ecosystem Kathleen.dhondt@ewi.vlaanderen.be FLANDERS: Key Figures 2017 Flanders: a high-income region with an open economy in the core of Europe Population: 6.50 million (= 57,5%
3ª MESA: QUÉ UTILIDAD OFRECE EL BIG DATA?
3ª MESA: QUÉ UTILIDAD OFRECE EL BIG DATA? Jesús M. Hernández Rivas Instituto de Investigación Biomédica de Salamanca. Universidad de Salamanca. Servicio de Hematología. Hospital Universitario de Salamanca.
SCP Workshop. Licensing & Health /////////// The real life / D. Immler
SCP Workshop Licensing & Health /////////// The real life 2018-12-04 / D. Immler Bayer is proud of its long-standing commitment to R&D Continuous Investment in R&D Projects Input Output Other 55 million
Translational Research
Translational Research Paddy Johnston Chair, MRC Translational Research Overview Group October 2012 Translational Research Strategy and its delivery To accelerate patient benefit and increase economic
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
State of play and outlook
Health in Horizon 2020 State of play and outlook European High level meeting Madrid, 2 nd October 2012 Didier Gambier, Head of the Horizontal Aspects Unit, Health Directorate Directorate-General for European
The International Consortium for Personalised Medicine
The International Consortium for Personalised Medicine Mairead O Driscoll Alliance for Biomedical Research in Europe, 8 November 2017 Personalised Medicine A definition Characterisation of individuals
Topic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
CNS Clinical Trials: Suicidality and Data Collection. Ways to Facilitate Collaboration: How and Who?
CNS Clinical Trials: Suicidality and Data Collection Ways to Facilitate Collaboration: How and Who? ShaAvhree Buckman, M.D., Ph.D. Acting Director Office of Translational Sciences Center for Drug Evaluation
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
Research Centre for Natural Sciences Hungarian Academy of Sciences Institute of Enzymology
Research Centre for Natural Sciences Hungarian Academy of Sciences Institute of Enzymology Director: László Buday Dávid Szüts Genome Stability Research Group University Campus of Lágymányos BUDAPEST UNIVERSITY
Research & Innovation in food, health and ageing
Research & Innovation in food, health and ageing Feasibility study on dietary recommendations for older adults in the European Union 23-24 October 2014 Ispra, IT Isabelle de Froidmont-Görtz European Commission
-YOUR PARTNER IN RESEARCH AND DEVELOPMENT
-YOUR PARTNER IN RESEARCH AND DEVELOPMENT WHY CHOOSE NORWAY? A healthcare system with great opportunities for research....... 2 Unique and accessible health registries and biobanks........... 3 A great
BBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017
BBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017 BBMRI-NL TOWARDS A NATIONAL BIOBANKING INFRASTRUCTURE Founded in 2009 as the Dutch
INTERNATIONAL COLLABORATION. S. Sinha Adviser Department of Biotechnology Ministry of Science & Technology Government of India
INTERNATIONAL COLLABORATION S. Sinha Adviser Department of Biotechnology Ministry of Science & Technology Government of India INDIA S ASSETS Strong pool of scientists and engineers >300,000 institutions
EHRA Non Faculty Salary Structure
AA 1 Unused ~ Reserved for Future Use I Unused AA 2 Associate Vice Chancellors, Associate Provosts, II $128,100 $204,900 $300,400 Vice Provosts A1 Academic Administration/University Programs I $81,800
BACKGROUND AND PROSPECTS FOR THE FUTURE?
BACKGROUND AND PROSPECTS FOR THE FUTURE? Superbugs & Superdrugs London 5 th -6 th March 2014 R. Bax TranScrip Partners LLP Richard.Bax@transcrip-partners.com Contents 1. Background 2. Regulatory changes
European priorities in health research
7 april 2010 European priorities in health research The Dutch perspective Netherlands Federation of University Medical Centers Position paper Edited by: Ingeborg Meijer Wieneke Vullings Frank Zuijdam Table
AIT - Austrian Institute of Technology
BIOMARKER DISCOVERY, BIOINFORMATICS, AND BIOSENSOR DEVELOPMENT Technology Experience AIT Austrian Institute of Technology Low-Emission Transport AIT - Austrian Institute of Technology Energy Health & Bioresources
DBT-IIT Workshop. IIT Bombay Presentation. by Prof. Dulal Panda
DBT-IIT Workshop IIT Bombay Presentation by Prof. Dulal Panda 1 Research & Development 2 Faculty involved in Bio-research 15% faculty of institute actively involved in bio-research A wide-spectrum from
SMEs learn more about how to commercialise health related products at Lifescience Launchpad
Innovation Nexus Case Study 3 SMEs learn more about how to commercialise health related products at Lifescience Launchpad With such a diverse cohort of companies spanning drug development, diagnostics
Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline
R&D Strategy Bridging g the academia-industry industry yg gap Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline GSK at a glance Who we are We are a science-led global healthcare
Technology Transfer, Academic and Industry Cooperations
Technology Transfer, Academic and Industry Cooperations Jake Micallef PhD MBA COO ValiRx plc Visiting lecturer Simfonec Jake.micallef@valirx.com What do they want? Universities Money to fund research and